Interpretation 2217
Tier 1|
|
|
Primary Sites
Tumor Types
Interpretation
Crizotinib
Citations
- Paik PK, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5(8):842-9
- Awad MM, et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol 2016;34(7):721-30
- Frampton GM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5(8):850-9
Last updated: 2018-04-18 14:42:54 UTC